We are proud to announce our expected participation in SEEDS, an Advanced Research Projects Agency for Health (@ARPA_H)-funded research consortium co-led by the @BuckInstitute and @Georgetown, to measure how disease-causing proteins misfold before irreversible damage occurs in Alzheimer's disease and cancer. Many diseases begin with protein dysregulation, misfolding, and aggregation. Today, most treatments arrive only after irreversible damage has occurred. SEEDS aims to predict harmful changes in disease-causing proteins before that point and to use those predictions to develop new ways of detecting, slowing, and treating neurodegenerative diseases and cancer. The four-year consortium has been awarded up to $51.7 million through ARPA-H's BIOGAMI program. Upon completion of contracting, Nautilus would be expected to receive up to $6 million over the course of the program to deploy the Voyager™ Platform to quantify proteoforms of tau, implicated in Alzheimer's disease, and EWS::FLI1, implicated in the pediatric cancer Ewing sarcoma. The work would be anticipated to then extend to a larger set of intrinsically disordered proteins. The resulting data would be expected to be used to train AI models to predict how proteoforms push a protein toward aggregation. "We believe that the highly differentiated data from the Nautilus Voyager Platform has the potential to unlock a new generation of proteoform-enabled diagnostics and therapeutics." – Parag Mallick, Ph.D., Co-founder and Chief Scientist, Nautilus. medicine.georgetown.edu/news… #Proteomics #Proteoforms #AlzheimersDisease #EwingSarcoma